Inhibition of Translesion DNA Synthesis as a Novel Therapeutic Strategy to Treat Brain Cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Temozolomide (TMZ) is a standard chemotherapy for brain tumors.
• Drug resistance and limited efficacy are significant challenges in TMZ treatment.
• Targeting DNA repair mechanisms offers a potential strategy to overcome resistance.

Purpose of the Study:

• To evaluate the efficacy of combining TMZ with a novel artificial nucleoside, 5-nitroindolyl-2 -deoxyriboside (5-NIdR).
• To investigate the mechanism of action of 5-NIdR in inhibiting DNA lesion replication.
• To assess the safety and therapeutic potential of this combination therapy in preclinical models.

Main Methods:

• In vitro studies on human DNA polymerases.
• In vivo experiments using a murine glioblastoma xenograft model.
• Apoptosis assays and tumor growth inhibition measurements.
• Exploratory toxicology assessments.

Main Results:

• 5-NIdR is converted to a triphosphate form that inhibits DNA polymerases involved in replicating TMZ-induced DNA damage.
• The combination of TMZ and 5-NIdR synergistically increased tumor cell apoptosis.
• TMZ alone delayed tumor growth, while the combination with 5-NIdR led to complete tumor regression in mice.
• High doses of 5-NIdR showed no significant toxicity compared to conventional nucleoside analogs.

Conclusions:

• Coordinate inhibition of translesion DNA synthesis is a viable strategy to enhance chemotherapeutic responses.
• The combination of TMZ and 5-NIdR demonstrates significant preclinical efficacy and safety for aggressive brain tumors.
• This study provides a pharmacologic proof of concept for improving brain tumor treatment through novel drug combinations.